<!DOCTYPE html>
<html lang="en-us">

<head>

  <meta charset="utf-8">
  <meta name="viewport" content="width=device-width, initial-scale=1">
  <meta http-equiv="X-UA-Compatible" content="IE=edge">
  <meta name="generator" content="Source Themes Academic 4.8.0">

  

  
  
  
  
  
    
    
    
  
  

  

  
  
  
    
  
  <meta name="description" content="PURPOSE To identify the most effective multidentate 1,2-HOPO and Me-3,2-HOPO ligands for chelation of Pu(IV) in vivo. MATERIALS AND METHODS Two sets of ligands with four identical backbones were prepared containing two, three or four bidentate 1,2-HOPO or Me-3,2-HOPO groups, and 3,4,3-LI(1,2-HOPO) was resynthesized in a higher yielding procedure. They were evaluated in mouse for acute toxicity and reduction of tissue 238Pu, in comparison with CaNa3-DTPA (30 micromol kg(-1)). RESULTS Nine HOPO ligands, promptly injected or given orally or injected at low dosage, are superior to CaNa3-DTPA for reducing 238Pu retention in mouse. Five, given by delayed injection or promptly injected or orally administered as ferric complexes, are superior to CaNa3-DTPA or FeNa2-DTPA respectively. The Me-3,2-HOPO ligands are more effective than their structural 1,2-HOPO analogues, demonstrating the greater affinity of Me-3,2-HOPO for Pu(IV) in vivo. CONCLUSIONS The most efficacious ligand, 3,4,3-LI(1,2-HOPO), contains the less stably binding 1,2-HOPO group; therefore, its linear spermine backbone must confer advantages for Pu(IV) binding (greater solubility, more favorable arrangement of ligating groups, more flexible backbone). Effective low toxicity tetradentate 5-LIO(Me-3,2-HOPO) and hexadentate TREN-(Me-3,2-HOPO) and highly effective but moderately toxic 3,4,3-LI(1,2-HOPO) (LD50 approximately 300 micromol kg(-1) in mouse) are recommended for further investigation.">

  
  <link rel="alternate" hreflang="en-us" href="/publication/durbin-multidentate-2000/">

  


  
  
  
  <meta name="theme-color" content="#6baed6">
  

  
  

  
  
  
  
    
    <link rel="stylesheet" href="https://cdnjs.cloudflare.com/ajax/libs/academicons/1.8.6/css/academicons.min.css" integrity="sha256-uFVgMKfistnJAfoCUQigIl+JfUaP47GrRKjf6CTPVmw=" crossorigin="anonymous">
    <link rel="stylesheet" href="https://cdnjs.cloudflare.com/ajax/libs/font-awesome/5.12.0-1/css/all.min.css" integrity="sha256-4w9DunooKSr3MFXHXWyFER38WmPdm361bQS/2KUWZbU=" crossorigin="anonymous">
    <link rel="stylesheet" href="https://cdnjs.cloudflare.com/ajax/libs/fancybox/3.5.7/jquery.fancybox.min.css" integrity="sha256-Vzbj7sDDS/woiFS3uNKo8eIuni59rjyNGtXfstRzStA=" crossorigin="anonymous">

    
    
    
      
    
    

    
    <link rel="stylesheet" href="https://cdnjs.cloudflare.com/ajax/libs/leaflet/1.5.1/leaflet.css" integrity="sha256-SHMGCYmST46SoyGgo4YR/9AlK1vf3ff84Aq9yK4hdqM=" crossorigin="anonymous">
    

    

    
    
      

      
      

      
    
      

      
      

      
    
      

      
      

      
    
      

      
      

      
    
      

      
      

      
    
      

      
      

      
    
      

      
      

      
    
      

      
      

      
    
      

      
      

      
    
      

      
      

      
    
      

      
      

      
        <script src="https://cdnjs.cloudflare.com/ajax/libs/lazysizes/5.1.2/lazysizes.min.js" integrity="sha256-Md1qLToewPeKjfAHU1zyPwOutccPAm5tahnaw7Osw0A=" crossorigin="anonymous" async></script>
      
    
      

      
      

      
    
      

      
      

      
    
      

      
      
        
      

      
    
      

      
      

      
    

  

  
  
  
  <link rel="stylesheet" href="https://fonts.googleapis.com/css?family=Montserrat:400,700%7CRoboto:400,400italic,700%7CRoboto+Mono%7CMuli:400,700%7CRaleway%7CAnton%7CComfortaa:700%7CCatamaran:700&display=swap">
  

  
  
  
  
  <link rel="stylesheet" href="/css/academic.css">

  




  


  

  <link rel="manifest" href="/index.webmanifest">
  <link rel="icon" type="image/png" href="/images/icon_hu7e26b4628f129972ef79540a0bb720d6_10659_32x32_fill_lanczos_center_2.png">
  <link rel="apple-touch-icon" type="image/png" href="/images/icon_hu7e26b4628f129972ef79540a0bb720d6_10659_192x192_fill_lanczos_center_2.png">

  <link rel="canonical" href="/publication/durbin-multidentate-2000/">

  
  
  
  
  
    
    
  
  
  <meta property="twitter:card" content="summary">
  
  <meta property="og:site_name" content="HOPO Therapeutics">
  <meta property="og:url" content="/publication/durbin-multidentate-2000/">
  <meta property="og:title" content="Multidentate hydroxypyridinonate ligands for Pu(IV) chelation in vivo: comparative efficacy and toxicity in mouse of ligands containing 1,2-HOPO or Me-3,2-HOPO. | HOPO Therapeutics">
  <meta property="og:description" content="PURPOSE To identify the most effective multidentate 1,2-HOPO and Me-3,2-HOPO ligands for chelation of Pu(IV) in vivo. MATERIALS AND METHODS Two sets of ligands with four identical backbones were prepared containing two, three or four bidentate 1,2-HOPO or Me-3,2-HOPO groups, and 3,4,3-LI(1,2-HOPO) was resynthesized in a higher yielding procedure. They were evaluated in mouse for acute toxicity and reduction of tissue 238Pu, in comparison with CaNa3-DTPA (30 micromol kg(-1)). RESULTS Nine HOPO ligands, promptly injected or given orally or injected at low dosage, are superior to CaNa3-DTPA for reducing 238Pu retention in mouse. Five, given by delayed injection or promptly injected or orally administered as ferric complexes, are superior to CaNa3-DTPA or FeNa2-DTPA respectively. The Me-3,2-HOPO ligands are more effective than their structural 1,2-HOPO analogues, demonstrating the greater affinity of Me-3,2-HOPO for Pu(IV) in vivo. CONCLUSIONS The most efficacious ligand, 3,4,3-LI(1,2-HOPO), contains the less stably binding 1,2-HOPO group; therefore, its linear spermine backbone must confer advantages for Pu(IV) binding (greater solubility, more favorable arrangement of ligating groups, more flexible backbone). Effective low toxicity tetradentate 5-LIO(Me-3,2-HOPO) and hexadentate TREN-(Me-3,2-HOPO) and highly effective but moderately toxic 3,4,3-LI(1,2-HOPO) (LD50 approximately 300 micromol kg(-1) in mouse) are recommended for further investigation."><meta property="og:image" content="img/map[gravatar:%!s(bool=false) shape:square]">
  <meta property="twitter:image" content="img/map[gravatar:%!s(bool=false) shape:square]"><meta property="og:locale" content="en-us">
  
    
      <meta property="article:published_time" content="2020-04-05T05:18:33&#43;00:00">
    
    <meta property="article:modified_time" content="2000-02-01T00:00:00&#43;00:00">
  

  


    









<script type="application/ld+json">
{
  "@context": "https://schema.org",
  "@type": "Article",
  "mainEntityOfPage": {
    "@type": "WebPage",
    "@id": "/publication/durbin-multidentate-2000/"
  },
  "headline": "Multidentate hydroxypyridinonate ligands for Pu(IV) chelation in vivo: comparative efficacy and toxicity in mouse of ligands containing 1,2-HOPO or Me-3,2-HOPO.",
  
  "datePublished": "2020-04-05T05:18:33Z",
  "dateModified": "2000-02-01T00:00:00Z",
  
  "author": {
    "@type": "Person",
    "name": "P W Durbin"
  },
  
  "publisher": {
    "@type": "Organization",
    "name": "HOPO Therapeutics",
    "logo": {
      "@type": "ImageObject",
      "url": "/images/icon_hu7e26b4628f129972ef79540a0bb720d6_10659_192x192_fill_lanczos_center_2.png"
    }
  },
  "description": "PURPOSE To identify the most effective multidentate 1,2-HOPO and Me-3,2-HOPO ligands for chelation of Pu(IV) in vivo. MATERIALS AND METHODS Two sets of ligands with four identical backbones were prepared containing two, three or four bidentate 1,2-HOPO or Me-3,2-HOPO groups, and 3,4,3-LI(1,2-HOPO) was resynthesized in a higher yielding procedure. They were evaluated in mouse for acute toxicity and reduction of tissue 238Pu, in comparison with CaNa3-DTPA (30 micromol kg(-1)). RESULTS Nine HOPO ligands, promptly injected or given orally or injected at low dosage, are superior to CaNa3-DTPA for reducing 238Pu retention in mouse. Five, given by delayed injection or promptly injected or orally administered as ferric complexes, are superior to CaNa3-DTPA or FeNa2-DTPA respectively. The Me-3,2-HOPO ligands are more effective than their structural 1,2-HOPO analogues, demonstrating the greater affinity of Me-3,2-HOPO for Pu(IV) in vivo. CONCLUSIONS The most efficacious ligand, 3,4,3-LI(1,2-HOPO), contains the less stably binding 1,2-HOPO group; therefore, its linear spermine backbone must confer advantages for Pu(IV) binding (greater solubility, more favorable arrangement of ligating groups, more flexible backbone). Effective low toxicity tetradentate 5-LIO(Me-3,2-HOPO) and hexadentate TREN-(Me-3,2-HOPO) and highly effective but moderately toxic 3,4,3-LI(1,2-HOPO) (LD50 approximately 300 micromol kg(-1) in mouse) are recommended for further investigation."
}
</script>

  

  


  


  





  <title>Multidentate hydroxypyridinonate ligands for Pu(IV) chelation in vivo: comparative efficacy and toxicity in mouse of ligands containing 1,2-HOPO or Me-3,2-HOPO. | HOPO Therapeutics</title>

</head>

<body id="top" data-spy="scroll" data-offset="70" data-target="#TableOfContents" >

  <aside class="search-results" id="search">
  <div class="container">
    <section class="search-header">

      <div class="row no-gutters justify-content-between mb-3">
        <div class="col-6">
          <h1>Search</h1>
        </div>
        <div class="col-6 col-search-close">
          <a class="js-search" href="#"><i class="fas fa-times-circle text-muted" aria-hidden="true"></i></a>
        </div>
      </div>

      <div id="search-box">
        
        
        
      </div>

    </section>
    <section class="section-search-results">

      <div id="search-hits">
        
      </div>

    </section>
  </div>
</aside>


  







<nav class="navbar navbar-expand-lg navbar-light compensate-for-scrollbar" id="navbar-main">
  <div class="container">

    
    <div class="d-none d-lg-inline-flex">
      <a class="navbar-brand" href="/">HOPO Therapeutics</a>
    </div>
    

    
    <button type="button" class="navbar-toggler" data-toggle="collapse"
            data-target="#navbar-content" aria-controls="navbar" aria-expanded="false" aria-label="Toggle navigation">
    <span><i class="fas fa-bars"></i></span>
    </button>
    

    
    <div class="navbar-brand-mobile-wrapper d-inline-flex d-lg-none">
      <a class="navbar-brand" href="/">HOPO Therapeutics</a>
    </div>
    

    
    
    <div class="navbar-collapse main-menu-item collapse justify-content-end" id="navbar-content">

      
      <ul class="navbar-nav d-md-inline-flex">
        

        

        
        
        

        
        
        
        
        
        

        <li class="nav-item">
          <a class="nav-link " href="/#"><span>Home</span></a>
        </li>

        
        

        

        
        
        
          
        

        
        
        
        
        
        
          
          
          
            
          
          
        

        <li class="nav-item">
          <a class="nav-link " href="/#posts"><span>News</span></a>
        </li>

        
        

        

        
        
        
          
        

        
        
        
        
        
        

        <li class="nav-item">
          <a class="nav-link " href="/science/"><span>Science</span></a>
        </li>

        
        

        

        
        
        
          
        

        
        
        
        
        
        

        <li class="nav-item">
          <a class="nav-link " href="/about/"><span>About</span></a>
        </li>

        
        

        

        
        
        
          
        

        
        
        
        
        
        
          
          
          
            
          
          
        

        <li class="nav-item">
          <a class="nav-link " href="/#contact"><span>Contact</span></a>
        </li>

        
        

      

        
      </ul>
    </div>

    <ul class="nav-icons navbar-nav flex-row ml-auto d-flex pl-md-2">
      

      

      

    </ul>

  </div>
</nav>


  <div class="pub">

  












  

  
  
  
<div class="article-container pt-3">
  <h1>Multidentate hydroxypyridinonate ligands for Pu(IV) chelation in vivo: comparative efficacy and toxicity in mouse of ligands containing 1,2-HOPO or Me-3,2-HOPO.</h1>

  

  
    


<div class="article-metadata">

  
  
  
  
  <div>
    

  
  <span>P W Durbin</span>, <span>B Kullgren</span>, <span>J Xu</span>, <span>K N Raymond</span>
  </div>
  
  

  
  <span class="article-date">
    
    
      
    
    February 2000
  </span>
  

  

  

  
  
  

  
  

</div>

    











  



<div class="btn-links mb-3">
  
  








  
    
  



<a class="btn btn-outline-primary my-1 mr-1" href="http://www.ncbi.nlm.nih.gov/pubmed/10716641" target="_blank" rel="noopener">
  PDF
</a>



<button type="button" class="btn btn-outline-primary my-1 mr-1 js-cite-modal"
        data-filename="/publication/durbin-multidentate-2000/cite.bib">
  Cite
</button>













<a class="btn btn-outline-primary my-1 mr-1" href="https://doi.org/10.1080/095530000138853" target="_blank" rel="noopener">
  DOI
</a>



</div>


  
</div>



  <div class="article-container">

    
    <h3>Abstract</h3>
    <p class="pub-abstract">PURPOSE To identify the most effective multidentate 1,2-HOPO and Me-3,2-HOPO ligands for chelation of Pu(IV) in vivo. MATERIALS AND METHODS Two sets of ligands with four identical backbones were prepared containing two, three or four bidentate 1,2-HOPO or Me-3,2-HOPO groups, and 3,4,3-LI(1,2-HOPO) was resynthesized in a higher yielding procedure. They were evaluated in mouse for acute toxicity and reduction of tissue 238Pu, in comparison with CaNa3-DTPA (30 micromol kg(-1)). RESULTS Nine HOPO ligands, promptly injected or given orally or injected at low dosage, are superior to CaNa3-DTPA for reducing 238Pu retention in mouse. Five, given by delayed injection or promptly injected or orally administered as ferric complexes, are superior to CaNa3-DTPA or FeNa2-DTPA respectively. The Me-3,2-HOPO ligands are more effective than their structural 1,2-HOPO analogues, demonstrating the greater affinity of Me-3,2-HOPO for Pu(IV) in vivo. CONCLUSIONS The most efficacious ligand, 3,4,3-LI(1,2-HOPO), contains the less stably binding 1,2-HOPO group; therefore, its linear spermine backbone must confer advantages for Pu(IV) binding (greater solubility, more favorable arrangement of ligating groups, more flexible backbone). Effective low toxicity tetradentate 5-LIO(Me-3,2-HOPO) and hexadentate TREN-(Me-3,2-HOPO) and highly effective but moderately toxic 3,4,3-LI(1,2-HOPO) (LD50 approximately 300 micromol kg(-1) in mouse) are recommended for further investigation.</p>
    

    
    <div class="row">
      <div class="col-md-1"></div>
      <div class="col-md-10">
        <div class="row">
          <div class="col-12 col-md-3 pub-row-heading">Type</div>
          <div class="col-12 col-md-9">
            
            
            <a href="/publication/#2">
              Journal article
            </a>
            
          </div>
        </div>
      </div>
      <div class="col-md-1"></div>
    </div>
    <div class="d-md-none space-below"></div>
    

    
    <div class="row">
      <div class="col-md-1"></div>
      <div class="col-md-10">
        <div class="row">
          <div class="col-12 col-md-3 pub-row-heading">Publication</div>
          <div class="col-12 col-md-9"><em>International journal of radiation biology</em></div>
        </div>
      </div>
      <div class="col-md-1"></div>
    </div>
    <div class="d-md-none space-below"></div>
    

    <div class="space-below"></div>

    <div class="article-style"></div>

    





<div class="share-box" aria-hidden="true">
  <ul class="share">
    
      
      
      
        
      
      
      
      <li>
        <a href="https://twitter.com/intent/tweet?url=/publication/durbin-multidentate-2000/&amp;text=Multidentate%20hydroxypyridinonate%20ligands%20for%20Pu%28IV%29%20chelation%20in%20vivo:%20comparative%20efficacy%20and%20toxicity%20in%20mouse%20of%20ligands%20containing%201,2-HOPO%20or%20Me-3,2-HOPO." target="_blank" rel="noopener" class="share-btn-twitter">
          <i class="fab fa-twitter"></i>
        </a>
      </li>
    
      
      
      
        
      
      
      
      <li>
        <a href="https://www.facebook.com/sharer.php?u=/publication/durbin-multidentate-2000/&amp;t=Multidentate%20hydroxypyridinonate%20ligands%20for%20Pu%28IV%29%20chelation%20in%20vivo:%20comparative%20efficacy%20and%20toxicity%20in%20mouse%20of%20ligands%20containing%201,2-HOPO%20or%20Me-3,2-HOPO." target="_blank" rel="noopener" class="share-btn-facebook">
          <i class="fab fa-facebook"></i>
        </a>
      </li>
    
      
      
      
        
      
      
      
      <li>
        <a href="mailto:?subject=Multidentate%20hydroxypyridinonate%20ligands%20for%20Pu%28IV%29%20chelation%20in%20vivo:%20comparative%20efficacy%20and%20toxicity%20in%20mouse%20of%20ligands%20containing%201,2-HOPO%20or%20Me-3,2-HOPO.&amp;body=/publication/durbin-multidentate-2000/" target="_blank" rel="noopener" class="share-btn-email">
          <i class="fas fa-envelope"></i>
        </a>
      </li>
    
      
      
      
        
      
      
      
      <li>
        <a href="https://www.linkedin.com/shareArticle?url=/publication/durbin-multidentate-2000/&amp;title=Multidentate%20hydroxypyridinonate%20ligands%20for%20Pu%28IV%29%20chelation%20in%20vivo:%20comparative%20efficacy%20and%20toxicity%20in%20mouse%20of%20ligands%20containing%201,2-HOPO%20or%20Me-3,2-HOPO." target="_blank" rel="noopener" class="share-btn-linkedin">
          <i class="fab fa-linkedin-in"></i>
        </a>
      </li>
    
      
      
      
        
      
      
      
      <li>
        <a href="https://web.whatsapp.com/send?text=Multidentate%20hydroxypyridinonate%20ligands%20for%20Pu%28IV%29%20chelation%20in%20vivo:%20comparative%20efficacy%20and%20toxicity%20in%20mouse%20of%20ligands%20containing%201,2-HOPO%20or%20Me-3,2-HOPO.%20/publication/durbin-multidentate-2000/" target="_blank" rel="noopener" class="share-btn-whatsapp">
          <i class="fab fa-whatsapp"></i>
        </a>
      </li>
    
      
      
      
        
      
      
      
      <li>
        <a href="https://service.weibo.com/share/share.php?url=/publication/durbin-multidentate-2000/&amp;title=Multidentate%20hydroxypyridinonate%20ligands%20for%20Pu%28IV%29%20chelation%20in%20vivo:%20comparative%20efficacy%20and%20toxicity%20in%20mouse%20of%20ligands%20containing%201,2-HOPO%20or%20Me-3,2-HOPO." target="_blank" rel="noopener" class="share-btn-weibo">
          <i class="fab fa-weibo"></i>
        </a>
      </li>
    
  </ul>
</div>












  
    
    





  
  
  
  
  
  <div class="media author-card content-widget-hr">
    

    <div class="media-body">
      <h5 class="card-title"><a href="/authors/p-w-durbin/"></a></h5>
      
      
      <ul class="network-icon" aria-hidden="true">
  
</ul>

    </div>
  </div>


  
    
    





  
  
  
  
  
  <div class="media author-card content-widget-hr">
    

    <div class="media-body">
      <h5 class="card-title"><a href="/authors/b-kullgren/"></a></h5>
      
      
      <ul class="network-icon" aria-hidden="true">
  
</ul>

    </div>
  </div>


  
    
    





  
  
  
  
  
  <div class="media author-card content-widget-hr">
    

    <div class="media-body">
      <h5 class="card-title"><a href="/authors/j-xu/"></a></h5>
      
      
      <ul class="network-icon" aria-hidden="true">
  
</ul>

    </div>
  </div>


  
    
    





  
  
  
  
  
  <div class="media author-card content-widget-hr">
    

    <div class="media-body">
      <h5 class="card-title"><a href="/authors/k-n-raymond/"></a></h5>
      
      
      <ul class="network-icon" aria-hidden="true">
  
</ul>

    </div>
  </div>


  










  
  



  </div>
</div>

      

    
    
    
      <script src="https://cdnjs.cloudflare.com/ajax/libs/jquery/3.4.1/jquery.min.js" integrity="sha256-CSXorXvZcTkaix6Yvo6HppcZGetbYMGWSFlBw8HfCJo=" crossorigin="anonymous"></script>
      <script src="https://cdnjs.cloudflare.com/ajax/libs/jquery.imagesloaded/4.1.4/imagesloaded.pkgd.min.js" integrity="sha256-lqvxZrPLtfffUl2G/e7szqSvPBILGbwmsGE1MKlOi0Q=" crossorigin="anonymous"></script>
      <script src="https://cdnjs.cloudflare.com/ajax/libs/jquery.isotope/3.0.6/isotope.pkgd.min.js" integrity="sha256-CBrpuqrMhXwcLLUd5tvQ4euBHCdh7wGlDfNz8vbu/iI=" crossorigin="anonymous"></script>
      <script src="https://cdnjs.cloudflare.com/ajax/libs/fancybox/3.5.7/jquery.fancybox.min.js" integrity="sha256-yt2kYMy0w8AbtF89WXb2P1rfjcP/HTHLT7097U8Y5b8=" crossorigin="anonymous"></script>

      

      

    

    
    
      <script src="https://cdnjs.cloudflare.com/ajax/libs/leaflet/1.5.1/leaflet.js" integrity="sha256-EErZamuLefUnbMBQbsEqu1USa+btR2oIlCpBJbyD4/g=" crossorigin="anonymous"></script>
    

    
    
    <script>const code_highlighting = false;</script>
    

    
    
    <script>const isSiteThemeDark = false;</script>
    

    

    
    

    

    
    

    
    

    
    

    
    
    
    
    
    
    
    
    
    
    
    
    <script src="/js/academic.min.6f7ce8be710290b8c431bbc97f405d15.js"></script>

    






  
  
  <div class="container">
    <footer class="site-footer">
  
  <p class="powered-by">
    
      <a href="/privacy/">Privacy Policy</a>
    
    
       &middot; 
      <a href="/terms/">Terms & Conditions</a>
    
  </p>
  

  <p class="powered-by">
    © 2020 HOPO Therapeutics, Inc. &middot; All Rights Reserved 

    
    <span class="float-right" aria-hidden="true">
      <a href="#" class="back-to-top">
        <span class="button_icon">
          <i class="fas fa-chevron-up fa-2x"></i>
        </span>
      </a>
    </span>
    
  </p>
</footer>

  </div>
  

  
<div id="modal" class="modal fade" role="dialog">
  <div class="modal-dialog">
    <div class="modal-content">
      <div class="modal-header">
        <h5 class="modal-title">Cite</h5>
        <button type="button" class="close" data-dismiss="modal" aria-label="Close">
          <span aria-hidden="true">&times;</span>
        </button>
      </div>
      <div class="modal-body">
        <pre><code class="tex hljs"></code></pre>
      </div>
      <div class="modal-footer">
        <a class="btn btn-outline-primary my-1 js-copy-cite" href="#" target="_blank">
          <i class="fas fa-copy"></i> Copy
        </a>
        <a class="btn btn-outline-primary my-1 js-download-cite" href="#" target="_blank">
          <i class="fas fa-download"></i> Download
        </a>
        <div id="modal-error"></div>
      </div>
    </div>
  </div>
</div>

</body>
</html>
